• Overview
  • Eligibility
  • More info
  • Locations

Treatment Adherence in Patients With Rheumatoid Arthritis Previously Treated With Oral or Injectable Methotrexate and Requiring a New Treatment With Injectable Methotrexate (NCT02897817)

The aim of this study is to evaluate, at 6 months, the rate of patients whose adherence to injectable MTX remained strong or improved according to patient-reported outcome.
Ages eligible for Study
18 Years and older
Genders eligible for Study
All
Accepts Healthy Volunteers
No
Inclusion Criteria:
  • Adult patients (≥ 18 years old)
  • Patients with a diagnosis of RA as confirmed by the ACR/EULAR (2010) Classification Criteria for Rheumatoid Arthritis
  • Patients:
  • currently treated with oral MTX and requiring a switch to an injectable MTX* or
  • currently treated with an injectable MTX* and eligible for a change of MTX injection device*
  • Patients informed about and accepting the computer processing of their medical data and their right of accesss and correction.
Exclusion Criteria:
  • Patients who refuse to participate in the study or are unable to fill out the patient diary. *On the basis of the products marketed at the time of submission of the study to Oversight Authorities (Méthotrexate Biodim®, Metoject® and imeth®).

1 locations

France (1)
  • Nordic Pharma
    Not specified
    Paris, France, 75007
Status:
active not recruiting
Type:
Observational
Phase:
-
Start:
31 May, 2016
Updated:
15 August, 2017
Participants:
560
A girl giving information about available additional trials.

FindMeCure helps you find, understand and join clinical trials from all over the world.

There are more clinical trials for your condition!